- Global Pharma News & Resources

Biopharmaceuticals and Biomedicine Market is geared to grow at a CAGR of 9.1% from 2023 to 2032 | insightSLICE

The global Biopharmaceuticals and Biomedicine market size was estimated to be US$ 550 billion in 2021 and is expected grow at a CAGR of 9.1% between 2023 to 2032.

The pharmaceutical industry’s leading sector, biopharmaceuticals, has had notable growth over the past few years and has tremendous development potential.

Access the sample report:

The global market for biopharmaceuticals and biomedicine is changing rapidly, despite the fact that the cost of biopharmaceuticals is much higher than that of traditional drugs due to the rising need for treatment options and increasing individual healthcare spending.

During the projected timeline, the rising prevalence of the chronic condition and rising R&D spending are also expected to play a significant role in driving demand for biopharmaceuticals and biomedicines.

The key players of the Global Biopharmaceuticals and Biomedicine Market are:

Major players dominating the global biopharmaceuticals and biomedicine market include Pfizer, Amgen Inc., AbbVie Inc., Affimed N.V., Bristol – Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche AG, Celgene Corporation, Johnson & Johnson, Novartis AG, NanoString Technologies, Inc., Novo Nordisk A/S, Inc., Qiagen N.V., and Sanofi S.A.

The report also takes the competitive environment into account, and as a result, it will provide company overviews and market forecasts for the top companies in the Biopharmaceuticals and Biomedicine Market.

What are the main factors covered in this report?

The report would cover important advancements, global and regional company networks, business strategies, security and exchange overviews, R&D initiatives, production facilities, product portfolios, staff strength, and key executives for all the companies taken into account for the study.

As an illustration, Novartis AG recorded revenues of US$ 51,900 Million in 2018. According to the segment of regional analysis, the Innovative Medicines core business led income in 2018, with the United States and Europe accounting for 69% of the total.

With an emphasis on major categories, this report offers an in-depth analysis of leading companies with a majority share of the global market. It would help identify the business sector that focuses on biopharmaceuticals and biomedicine.

Read more about the report inclusions:

Additionally, a company’s market position in the global market for biopharmaceuticals and biomedicine would be assessed. As an illustration, Novartis AG runs its operations through three segments: Innovative Medicines, Sandoz, and Alcon.

With a sales commitment of US$9.9 billion in 2018, the firm’s Sandoz business segment provides biopharmaceuticals and biomedicine. All of the biopharmaceuticals and biomedicine firms’ business strategies, product portfolios, important developments, SWOT analyses, and R&D priorities are taken into account in the study.

The study of the global market for biopharmaceuticals and biomedicine will also take into account the contributions made by each participant in the market’s supply and value chains.

Product profiles with examples:

The products that fall under the firm’s biopharmaceuticals and biomedicine market business area would be the main emphasis of our product portfolio segment.

Similarly, the current developments section would concentrate on the company’s most recent activities in the global biopharmaceuticals and biomedicine sector such as alliances and collaborations, acquisitions, product launch, and geographic segments.

For example, Endocyte, a US-based biopharmaceutical business that focuses on creating tailored therapies for the treatment of cancer, was acquired by Novartis AG in December 2018 for roughly US$ 2.1 billion.

To meet the growing demand from the worldwide market, major companies in the biopharmaceuticals and biomedicine market are firmly focusing on creating advanced biopharmaceuticals and biomedicine.

Related reports:

Global Bionic Ear Market:

Global Reprocessed Medical Devices Market:

Global Biopharmaceuticals and Biomedicine Market Key Segments:

By Product

  • Biopharmaceutical
    • Monoclonal Antibodies
    • Vaccines
    • Recombinant Human Insulin
    • Human Growth Hormone
    • Erythropoietin
    • Interferon
    • Colony Stimulating Factor
    • Blood Factors
    • Fusion Protein
    • Others
  • Nanomedicine
  • Cell & Gene Therapy
  • Bioinformatics
  • Molecular Enzymes & Kits

By Disease Type

  • Oncology
  • Neuroscience
  • Infectious disease
  • Immunology
  • Hematology
  • Hemophilia
  • Ophthalmology
  • Respiratory
  • Others

By Application

  • Therapeutics
  • Diagnostics
  • Research & Development

By Geography:

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

Regional performance of Biopharmaceuticals and Biomedicine Market

Due to the swift development of the healthcare system and the sustained uptake of biopharmaceuticals, North America led the global market for biopharmaceuticals and biomedicine.

Possible factors encouraging the expansion of the North American biopharmaceutical and biomedicine market include the country’s outstanding network for research and development and its simple insurance coverage procedures.

Due to the low demand in this region, it is projected that biopharmaceuticals will continue to be adopted steadily throughout the Asia Pacific.

Proceed to purchase:

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at

Contact us:

Alex R

+1 707 736 6633

Linkedin | Twitter

Editor Details

Last Updated: 25-Nov-2022